Efficacy and Safety of Rapamycin to Complex Vascular Anomalies in Pediatric Patients
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
KHE and TA are rare tumors and some of the cases may lead to life-threatening complications
including Kasabach-Merritt Phenomenon. Typically treated with steroids and vincristine, a
majority of the cases do not have good prognosis. Complex vascular malformations are always
managed by surgery,sclerotherapy and embolization therapy. While many of the cases still lead
to complications such as disfigurement, chronic pain, recurrent infections, coagulopathies.
Different medical centers are exploring new therapy for these tough problems. This study is
plotted to determine the efficacy and safety of rapamycin monotherapy in KHE/TA and complex
vascular malformations in pediatric patients.